CONCLUSIONS: Among men with testicular seminoma, RPLND was not associated with a survival benefit. Higher risk men undergo RPLND compared to radiation therapy as evidenced by differences in survival. Given that current use of RPLND is largely limited to the post-chemotherapy setting, upcoming trials implementing RPLND as a first-line modality for testicular seminoma will help quantify relative recurrence and survival tradeoffs.
INTRODUCTION AND OBJECTIVES: Elevated neutrophil-tolymphocyte ratio (NLR) has been reported to be a poor prognostic indicator in several malignancies and associated with response to immune checkpoint inhibitors; however the association with testicular cancer has not been evaluated. We explore the association between NLR on staging of testicular germ cell tumors (TGCT).
METHODS: Retrospective review of institutional testicular tumor database from 2010-2016. Patients with non-TGCT were excluded. Patients were categorized as localized or non-localized based on the presence of retroperitoneal or distant metastasis or elevated serum tumor markers following orchiectomy. Pre-and post-orchiectomy mean serum NLR and was calculated for patients and correlated with disease state. NLR > 4 was assessed separately based on previously reported correlation of this cut-point with prognosis in other malignancies. ROC analysis was used to determine accuracy of the NLR to distinguish patients presenting with clinically non-localized disease.
RESULTS: 159 pts with TGCT were identified for analysis: seminoma (n¼59), NSGCT (n¼97), ITGCN (n¼2), unknown (n¼1). Preand post-orchiectomy NLR was available for 61 and 56 patients, respectively. Mean NLR was significantly higher for patients with nonlocalized TGCT (Table) . ROC analysis (Figure) demonstrated that preorchiectomy NLR was associated with the presence of non-localized disease (AUC 0.770, p<0.001), while post-orchiectomy NLR trended toward significance (AUC 0.659, p¼0.063) as a factor associated with the presence of non-localized disease. Additionally, mean pre-orchiectomy NLR demonstrated a dose-response relationship with IGCCCG risk grouping for metastatic TGCT: good risk -NLR 4.6AE4.0, intermediate risk -NLR 5.7AE3.4, poor risk -NLR 13.2AE9.8, (p¼0.013).
CONCLUSIONS: NLR appears to be predictive of non-localized TGCT. Application of NLR may be useful as a predictive biomarker in a number of settings in which presence or degree of non-localized disease is in question e.g. prior to post-chemotherapy RPLND. Further validation is required. described an association between immunohistochemical CXCL12 expression and a decreased relapse rate in stage 1 non-seminoma patients. Therefore CXCL12 might be a clinically useful biomarker to allocate patients with stage 1 non-seminoma to adjuvant therapy vs. active surveillance. The aim of our study was to externally validate the results of Gilbert et al. and to assess the utility of CXCL12 as prognostic marker in patients with metastatic disease.
METHODS: A tissue micro array was constructed with tissue cores of 152 seminoma, 113 non-seminoma and 14 non-cancer patients, diagnosed in the period from 2004-2014. All tumor components were represented by two tissue cores (diameter 0.6 mm). If more than one tumor component was present in case of non-seminoma, each component was separately punched and represented on the tissue microarray. Immunohistochemical staining of TMA sections with CXCL12 antibody (Antibody 79018, 1:100; R&D Systems) was performed. The amount and the intensity of positive stained cells were analyzed using a semi-quantitative score.
RESULTS: Of 267 GCT patients, 31 out of 153 (20.3%) seminoma and 54 out of 114 (47.3%) non-seminoma patients were diagnosed with metastatic disease. Within all 1201 tissue cores CXCL12 expression was found in 0.2% of seminomatous components, 88.2% of yolk sac tumors, 43.3% of teratomas, 100% of choriocarcinomas, 30.6% of embryonal carcinoma, 0% of Germ cell neoplasia in situ (GCNIS) and 0% in normal tissue. With focus on non-seminoma patients, CXCL12 was expressed in 30 out of 60 (50%) localized and 27 out of 54 (50%) metastatic patients. After a median follow-up of 5.2 years (IQR 3.2-8.5) follow-up was available for 260 patients (98%) of which 36 (13.8%) recurred. In localized non-seminoma patients 7 out of 29 (24.1%) CXCL12 positive patients recurred compared to 4 out of 23 (14.8%) CXCL12 negative patients (p¼0.506). In metastatic non-seminoma patients 11 out of 12 (91.7%) CXCL12 positive patients compared to 1 out of 25 (4.0%) CXCL12 negative patients showed disease relapse after initial chemotherapy (p¼0.001).
CONCLUSIONS: CXCL12 is almost exclusively expressed in non-seminoma and absent in seminoma, normal tissue or GCNIS. The reported association between CXCL12 expression and lower recurrence rates in stage 1 non-seminoma patients could not be reproduced in our dataset. However our analysis suggests that CXCL12 expression is a risk factor for recurrence in metastatic non-seminoma patients. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1087
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